Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemoporfin PDT for Port-wine Birthmarks
NCT05171894Phase 2Recruiting
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Jan 2027
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hemoporfin in port-wine stain, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: Incidence of any local and systemic adverse events in Stage One at 44 weeks and Port Wine Birthmark-Investigator Global Assessment scale score reduction in Stage Two at 44 weeks. Started Sep 2024; status: recruiting.
02
Drugs
hemoporfin
03
Conditions
port-wine stain
Beyond the preview
Go deeper on NCT05171894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171894.